Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
Journal: Cancer cell
Published: June 13, 2023
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Journal: Haematologica
Published: March 10, 2021
MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.
Journal: Blood cancer journal
Published: August 19, 2020
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Journal: Cell reports
Published: July 30, 2020
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Journal: The Journal of clinical investigation
Published: June 01, 2018
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Journal: British journal of haematology
Published: February 01, 2018
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Journal: Nature communications
Published: December 12, 2016
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Journal: The Journal of clinical investigation
Published: December 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Journal: Cancer cell
Published: November 22, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026